Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations.

Autor: Kerzeli IK, Lord M, Doroszko M, Elgendy R, Chourlia A, Stepanek I, Larsson E, van Hooren L, Nelander S, Malmstrom PU, Dragomir A, Segersten U, Mangsbo SM

Publikováno v: PloS one [PLoS One] 2024 May 31; Vol. 19 (5), pp. e0304890. Date of Electronic Publication: 2024 May 31 (Print Publication: 2024).

Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model.

Autor: Ibrahim EIK; Department of Pharmacy, Uppsala University, Uppsala, Sweden., Ellingsen EB; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; Ultimovacs ASA, Oslo, Norway., Mangsbo SM; Department of Pharmacy, Uppsala University, Uppsala, Sweden; Ultimovacs AB, Uppsala, Sweden., Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden. Electronic address: lena.friberg@farmaci.uu.se.

Publikováno v: International immunopharmacology [Int Immunopharmacol] 2024 Jan 05; Vol. 126, pp. 111225. Date of Electronic Publication: 2023 Nov 20.

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.

Autor: Kerzeli IK; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Kostakis A; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Türker P; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden., Malmström PU; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden., Hemdan T; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden., Mezheyeuski A; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Ward DG; Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK., Bryan RT; Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK., Segersten U; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden., Lord M; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Mangsbo SM; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. sara.mangsbo@farmaci.uu.se.

Publikováno v: BMC cancer [BMC Cancer] 2023 Jun 30; Vol. 23 (1), pp. 605. Date of Electronic Publication: 2023 Jun 30.

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.

Autor: Ellingsen EB; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway. espen.ellingsen@ultimovacs.com.; Faculty of Medicine, University of Oslo, Oslo, Norway. espen.ellingsen@ultimovacs.com.; Ultimovacs ASA, Oslo, Norway. espen.ellingsen@ultimovacs.com., Bounova G; ENPICOM B.V., DA 's-Hertogenbosch, Netherlands., Kerzeli I; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Anzar I; NEC Oncoimmunity, Oslo, Norway., Simnica D; Department for Internal Medicine IV - Hematology and Oncology, Universitätsklinikum Halle (Saale), Halle, Germany., Aamdal E; Department of Oncology, Oslo University Hospital, Oslo, Norway., Guren T; Department of Oncology, Oslo University Hospital, Oslo, Norway., Clancy T; NEC Oncoimmunity, Oslo, Norway., Mezheyeuski A; HistoOne AB, Uppsala, Sweden., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Mangsbo SM; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.; Ultimovacs AB, Uppsala, Sweden., Binder M; Department for Internal Medicine IV - Hematology and Oncology, Universitätsklinikum Halle (Saale), Halle, Germany., Hovig E; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway., Gaudernack G; Ultimovacs ASA, Oslo, Norway.

Publikováno v: Journal of translational medicine [J Transl Med] 2022 Sep 11; Vol. 20 (1), pp. 419. Date of Electronic Publication: 2022 Sep 11.

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses.

Autor: Mangsbo SM; Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Havervall S; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden., Laurén I; Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Lindsay R; Department of Medical Cell Biology, Science for Life Laboratory Uppsala University, Uppsala, Sweden., Jernbom Falk A; Department of Protein Science Division of Protein Technology, KTH Royal Institute of Technology, Stockholm, Sweden., Marking U; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden., Lord M; Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Buggert M; Department of Medicine, Centre for Infectious Medicine, Karolinska Institute, Stockholm, Sweden., Dönnes P; SciCross AB, Skövde, Sweden., Christoffersson G; Department of Medical Cell Biology, Science for Life Laboratory Uppsala University, Uppsala, Sweden., Nilsson P; Department of Protein Science Division of Protein Technology, KTH Royal Institute of Technology, Stockholm, Sweden., Hober S; Department of Protein Science Division of Affinity Proteomics, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden., Phillipson M; Department of Medical Cell Biology, Science for Life Laboratory Uppsala University, Uppsala, Sweden., Klingström J; Department of Medicine, Centre for Infectious Medicine, Karolinska Institute, Stockholm, Sweden., Thålin C; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.

Publikováno v: PloS one [PLoS One] 2021 Sep 30; Vol. 16 (9), pp. e0258041. Date of Electronic Publication: 2021 Sep 30 (Print Publication: 2021).